Overview: DRVVT Confirm TestIntroduction: The DRVVT Confirm Test confirms lupus anticoagulant presence to diagnose antiphospholipid syndrome, causing blood clots or pregnancy complications, aiding in treatment planning. Affecting 1 in 2,000 people, antiphospholipid syndrome poses diagnostic challenges due to variable presentation. Following 2023 International Society on Thrombosis and Haemostasis (ISTH) guidelines, it uses coagulation assay for high specificity, supporting coagulation screening. This test is vital for diagnosis, therapy adjustment, and improving outcomes in hematology.
Other Names: Lupus Anticoagulant Confirmation Test, DRVVT Verification Assay.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic reliability.
Historical Milestone: Anticoagulant testing began in the 1980s with research by Exner, who developed DRVVT. Assay refinements in the 2000s by Siemens improved detection, surpassing earlier mixing studies.
Purpose: Confirms lupus anticoagulant to diagnose antiphospholipid syndrome, guides anticoagulation therapy, and evaluates patients with clots, aiming to prevent recurrence.
Test Parameters: DRVVT confirmation
Pretest Condition: No special preparation required. Collect plasma. Report history of clotting issues.
Specimen: Plasma (NaCit, 2-4 mL); 2 mL plasma in Na Citrate tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: 1 month
Medical History: Document blood clots or pregnancy issues. Include current medications or anticoagulant use.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., stroke), and sample collection risks.
Procedural Considerations: Uses coagulation assay to confirm DRVVT, requiring labs with coagulometers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Anticoagulants may alter results, requiring correlation.
Clinical Significance: Positive confirmation indicates syndrome, guiding therapy. Early treatment might prevent clots, while untreated cases lead to complications. Negative results may require retesting.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Anticardiolipin antibody, beta-2 glycoprotein, or ultrasound to confirm diagnosis.
Test Limitations: Specific to lupus anticoagulant; correlation with symptoms needed. False positives possible with other inhibitors.
References: ISTH Guidelines, 2023; Thrombosis and Haemostasis, Exner T, 2022.
